A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants
A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of the Oxyntomodulin Analog, LY2944876, in Healthy Japanese Subjects and Healthy Non-Japanese Subjects
Sponsor: OPKO Health, Inc.
Terminated
The termination criteria of the protocol was met during dose escalation.
Other terminated trials from OPKO Health, Inc.
- Chronic Kidney Disease stage3 · Phase PHASE3 · Jun 2024
- Chronic Kidney Diseases · Phase PHASE2 · Feb 2021
- Benign Prostatic Hyperplasia · Phase PHASE2 · Jun 2019
- Adult Growth Hormone Deficiency · Phase PHASE3 · Aug 2018
- Macular Degeneration · Phase PHASE3 · May 2009
More terminations from OPKO Health, Inc.
Other Healthy Volunteers trials with similar outcome
A PHASE1 clinical study on Healthy Volunteers, this trial is terminated or withdrawn. The trial is conducted by OPKO Health, Inc. and has accumulated 8 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
May 2021 — Jun 2021 [monthly]
Terminated PHASE1
-
Jan 2021 — May 2021 [monthly]
Terminated PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- OPKO Health, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .